Nimg-16. response assessment of bevacizumab therapy for glioblastoma treatment by using 11c-methionine, 18f-fluorothymidine and 18f-fluoromisonidazole pet tracers

CONCLUSION:Decreased changes in FMISO after bevacizumab therapy may be an useful biomarker for predicting PFS and OS in glioblastoma.

Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Miyake, K., Kouchi, M. Tags: NEURO-IMAGING Source Type: research